创新链/学科链/研发链/产业链

新药研发前沿动态 / 医药领域趋势进展

王文飞, 李德山. 成纤维细胞生长因子21在糖尿病中的转化应用研究进展[J]. 药学进展, 2019, 43(1): 29-33.
引用本文: 王文飞, 李德山. 成纤维细胞生长因子21在糖尿病中的转化应用研究进展[J]. 药学进展, 2019, 43(1): 29-33.
WANG Wenfei, LI Deshan. Research Advances in the Application of FGF-21 in Diabetes[J]. Progress in Pharmaceutical Sciences, 2019, 43(1): 29-33.
Citation: WANG Wenfei, LI Deshan. Research Advances in the Application of FGF-21 in Diabetes[J]. Progress in Pharmaceutical Sciences, 2019, 43(1): 29-33.

成纤维细胞生长因子21在糖尿病中的转化应用研究进展

Research Advances in the Application of FGF-21 in Diabetes

  • 摘要: 糖尿病及其并发症是目前导致人类死亡的主要原因之一。成纤维细胞生长因子21依托其优异的代谢调节能力和广泛的生物学活性,有望成为糖尿病治疗的理想药物。目前,国内已有多个成纤维细胞生长因子21类似物申请进入临床试验阶段,有望实现科研成果从实验室转化为科技生产力,从而真正为我国经济发展和社会进步服务。综述当前成纤维细胞生长因子21应用转化研究方面的进展。

     

    Abstract: Diabetes and its complications are the main causes for human death. Fibroblast growth factor 21 (FGF-21), with excellent ability for metabolic regulation and a wide range of biological functions, is identified as a potential lead for the development of anti-diabetic drug. Several FGF-21 analogs developed by domestic research teams have entered clinical trials and are expected to realize the conversion of scientific research achievements in laboratory to scientific and technological productivity, thus truly serving China's economic development and social progress. In this paper, the research progress of the application and transformation of FGF-21 was reviewed.

     

/

返回文章
返回